ライフサイエンスコーパス: attention deficit

1 with the body, suggesting a more generalized attention deficit.

2 d motor changes resembling hyperactivity and attention deficit.

3 le they are more resilient to stress-induced attention deficits.

4 isability (ID), and frequently presents with attention deficits.

5 diminished thalamic gain control can lead to attention deficits.

6 attery assessed both spatial and non-spatial attention deficits.

7 el treatments for psychiatric disorders with attention deficits.

8 by fMRI caused similar neglect-like spatial attention deficits.

9 The temporal dynamics of vigilant attention deficits across hours and days are driven by p

10 al disability, autism spectrum disorder, and attention-deficit activity disorder.

11 ntial that durably improves resistant visual attention deficits after brain injury.

12 erfluoroalkyl substances (PFAS) exposure and attention deficit and hyperactivity disorder (ADHD) is i

13 including Christianson syndrome, autism, and attention deficit and hyperactivity disorder.

14 tion has been linked to sensory abnormality, attention deficit and sleep disturbance across multiple

15 Attention deficits and cognitive performance were evalua

16 way as therapeutic targets in hyperactivity, attention deficit, and related psychiatric disorders.

17 was associated with greater psychopathology, attention deficits, and impulsiveness, with some effects

18 In macaques, the attention deficits associated with neglect can be readil

19 ies suggested that Chrna7 deficient mice had attention deficits, but were normal in baseline behavior

20 In particular, attention deficits can be detected before the epilepsy d

21 was effective in improving the debilitating attention deficits common to hemispatial neglect.

22 including anxiety and hyperactive behavior, attention deficit disorder, and seizures.

23 teria were systematic childhood diagnosis of attention-deficit disorder, ADHD, or a research diagnost

24 However, these various forms of attention deficits generally have abnormal microstructur

25 disorders, like autism spectrum disorders or attention-deficit hyper-activity disorders, which are kn

26 nd associated with autism spectrum (ASD) and attention deficit hyperactivity (ADHD) disorders.

27 n with autism spectrum disorder (ASD) and/or attention deficit hyperactivity disorder (ADHD) and 5,00

28 (FOV) act as a mediator between symptoms of attention deficit hyperactivity disorder (ADHD) and asso

29 in utero acetaminophen exposure and risks of attention deficit hyperactivity disorder (ADHD) and auti

30 Neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and auti

31 indexed by polygenic risk scores (PRSs) for attention deficit hyperactivity disorder (ADHD) and depr

32 reviously reported that children treated for attention deficit hyperactivity disorder (ADHD) and depr

33 genes play an vital role in the etiology of attention deficit hyperactivity disorder (ADHD) and its

34 ociated with autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and schi

35 number of psychiatric conditions, including attention deficit hyperactivity disorder (ADHD) and subs

36 ber of neuropsychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and, mor

37 Individuals with attention deficit hyperactivity disorder (ADHD) are at i

38 esses tied to the adult outcome of childhood attention deficit hyperactivity disorder (ADHD) could gu

39 ldren with autism spectrum disorder (ASD) or attention deficit hyperactivity disorder (ADHD) have 2-3

40 Attention deficit hyperactivity disorder (ADHD) is a com

41 Attention deficit hyperactivity disorder (ADHD) is a com

42 Attention deficit hyperactivity disorder (ADHD) is a com

43 Attention deficit hyperactivity disorder (ADHD) is a hig

44 Attention deficit hyperactivity disorder (ADHD) is a mul

45 d treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) is uncle

46 Impulsivity and inattention related to attention deficit hyperactivity disorder (ADHD) may incr

47 olescents and young adults without childhood attention deficit hyperactivity disorder (ADHD) often pr

48 Childhood attention deficit hyperactivity disorder (ADHD) shows a

49 This study examined the effects of childhood attention deficit hyperactivity disorder (ADHD) symptoms

50 tism, bipolar disorder, major depression and attention deficit hyperactivity disorder (ADHD) using ge

51 us brain regions in children and adults with attention deficit hyperactivity disorder (ADHD), althoug

52 e treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as freq

53 criptome-wide association studies (TWASs) of attention deficit hyperactivity disorder (ADHD), autism

54 Attention deficit hyperactivity disorder (ADHD), autism

55 ed executive inhibition is a core deficit of attention deficit hyperactivity disorder (ADHD), which i

56 n men to be diagnosed with schizophrenia and attention deficit hyperactivity disorder (ADHD), which s

57 s to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet ass

58 enia, cognition, educational attainment, and attention deficit hyperactivity disorder (ADHD).

59 s such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).

60 me, obsessive-compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD).

61 al brain regions in children and adults with attention deficit hyperactivity disorder (ADHD).

62 st widely used animal model for the study of attention deficit hyperactivity disorder (ADHD).

63 ted in multiple psychopathologies, including attention deficit hyperactivity disorder (ADHD).

64 to numerous psychiatric disorders including attention deficit hyperactivity disorder (ADHD).

65 y control and overall cognition in boys with attention deficit hyperactivity disorder (ADHD).

66 hich common genetic variants confer risk for attention deficit hyperactivity disorder (ADHD).

67 s [e.g., increased autism spectrum disorder, attention deficit hyperactivity disorder (ADHD)] in chil

68 associations of dyslexia risk with PGSs for attention deficit hyperactivity disorder (at p(T) = 0.05

69 (n associations = 17; n unique genes = 13), attention deficit hyperactivity disorder (n associations

70 , major depressive disorder (r(g)=0.26), and attention deficit hyperactivity disorder (r(g)=0.23), wh

71 mpanies neurodevelopmental disorders such as attention deficit hyperactivity disorder and autism spec

72 (mood and anxiety), behavioral disturbance (attention deficit hyperactivity disorder and conduct dis

73 lsivity, despite a frequent association with attention deficit hyperactivity disorder and impulse con

74 , with onset ranging from childhood, such as attention deficit hyperactivity disorder and intellectua

75 cts with DNA methylation in association with Attention Deficit Hyperactivity Disorder and Mental Deve

76 rders such as obsessive-compulsive disorder, attention deficit hyperactivity disorder and Tourette's

77 he study of monozygotic twins discordant for attention deficit hyperactivity disorder can elucidate m

78 ited understanding of why many children with attention deficit hyperactivity disorder do not outgrow

79 onding psychiatric disorders, depression and attention deficit hyperactivity disorder in independent

80 ed with neurotransmitter dysregulation, e.g. attention deficit hyperactivity disorder or Alzheimer's

81 hiatric disorders (autism spectrum disorders/attention deficit hyperactivity disorder).

82 ical disorders such as Huntington's disease, attention deficit hyperactivity disorder, and dementia,

83 er, alcohol use disorder, drug use disorder, attention deficit hyperactivity disorder, and personalit

84 adolescent psychopathology, such as anxiety, attention deficit hyperactivity disorder, and substance

85 es in children and adults, including autism, attention deficit hyperactivity disorder, asthma, and al

86 several neuropsychiatric disorders including attention deficit hyperactivity disorder, autism and bip

87 ur candidates under clinical development for attention deficit hyperactivity disorder, binge eating d

88 lycerides, type 2 diabetes, waist-hip ratio, attention deficit hyperactivity disorder, bipolar disord

89 but high variability in patients with autism/attention deficit hyperactivity disorder, compared with

90 Methylphenidate is used extensively to treat attention deficit hyperactivity disorder, even though it

91 tion disorder, N=52; anxiety disorder, N=42; attention deficit hyperactivity disorder, N=40; and heal

92 a clinical measure of attention--symptoms of attention deficit hyperactivity disorder--from resting-s

93 ce use disorders, pathological gambling, and attention deficit hyperactivity disorder.

94 ents, but lower variability in patients with attention deficit hyperactivity disorder.

95 r baseline tic severity, tic medication, and attention deficit hyperactivity disorder.

96 nsitions, symptoms typically associated with attention deficit hyperactivity disorder.

97 ariability changes between schizophrenia and attention deficit hyperactivity disorder/autism.

98 The extensive use of amphetamines to treat attention deficit hyperactivity disorders in children pr

99 polar disorder (BIP), major depression (MD), attention-deficit hyperactivity disorder (ADHD) and auti

100 ndings are mixed on the relationship between attention-deficit hyperactivity disorder (ADHD) and youn

101 ral studies have questioned the stability of attention-deficit hyperactivity disorder (ADHD) from chi

102 Previous studies of attention-deficit hyperactivity disorder (ADHD) have sug

103 Attention-deficit hyperactivity disorder (ADHD) is a com

104 Attention-deficit hyperactivity disorder (ADHD) is a neu

105 Attention-deficit hyperactivity disorder (ADHD) is a pre

106 Attention-deficit hyperactivity disorder (ADHD) is assoc

107 Although attention-deficit hyperactivity disorder (ADHD) is highl

108 he natural environment might protect against attention-deficit hyperactivity disorder (ADHD) or moder

109 For many years, attention-deficit hyperactivity disorder (ADHD) was thou

110 The cognitive mechanisms underlying attention-deficit hyperactivity disorder (ADHD), a highl

111 Attention-deficit hyperactivity disorder (ADHD), like ot

112 he most common pharmacological treatment for attention-deficit hyperactivity disorder (ADHD), might i

113 Attention-deficit hyperactivity disorder (ADHD), one of

114 ndings in autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD), the ent

115 =18 years) for treating depression, anxiety, attention-deficit hyperactivity disorder (ADHD), Tourett

116 osed with autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD).

117 Brain Imaging Data Exchange (ABIDE) and the Attention-Deficit Hyperactivity Disorder (ADHD-200) data

118 The risk of attention-deficit hyperactivity disorder (OR 6.9, 3.2-15

119 ic associations between the Pro33 allele and attention-deficit hyperactivity disorder and ASDs.

120 Overall we describe an increased rate of attention-deficit hyperactivity disorder and autism spec

121 ectual disability, autism spectrum disorder, attention-deficit hyperactivity disorder and Down syndro

122 ole in neuropsychiatric disorders, including attention-deficit hyperactivity disorder and drug addict

123 orders, including schizophrenia, depression, attention-deficit hyperactivity disorder and substance a

124 intellectual disability, facial dysmorphism, attention-deficit hyperactivity disorder) and revealed f

125 odevelopmental phenotypes, including autism, attention-deficit hyperactivity disorder, and speech and

126 ding intellectual disability, schizophrenia, attention-deficit hyperactivity disorder, autism spectru

127 associations of smoking with drug and AUDs, attention-deficit hyperactivity disorder, bipolar disord

128 ended as a key component in the treatment of attention-deficit hyperactivity disorder, their use cont

129 e disorders and symptoms, anxiety disorders, attention-deficit hyperactivity disorder, Tourette syndr

130 lopmental disorders, particularly autism and attention-deficit hyperactivity disorder.

131 epression, obsessive-compulsive disorder and attention-deficit hyperactivity disorder.

132 its underlying psychiatric disorders such as attention-deficit hyperactivity disorder.

133 evalence estimates of 28% (95% CI 25-32) for attention-deficit hyperactivity disorder; 20% (17-23) fo

134 al-reported symptoms of depression, anxiety, attention/deficit hyperactivity disorder (ADHD), opposit

135 enidate and amphetamine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been

136 risk of bipolar disorder, schizophrenia and attention deficit-hyperactivity disorder.

137 elations were found between extraversion and attention-deficit-hyperactivity disorder (ADHD) and betw

138 trum Disorder (ASD), schizophrenia (SZ), and Attention-Deficit-Hyperactivity-Disorder (ADHD), but the

139 gnaling in humans associated with addiction, attention-deficit/ hyperactivity disorder, schizophrenia

140 mental exposure to PBDEs and intelligence or Attention Deficit/Hyperactivity Disorder (ADHD) and atte

141 Attention deficit/hyperactivity disorder (ADHD) is a com

142 Attention deficit/hyperactivity disorder (ADHD) is a com

143 Attention deficit/hyperactivity disorder (ADHD) is a hig

144 features, including intellectual disability, attention deficit/hyperactivity disorder (ADHD), and aut

145 with preexisting attention problems, such as attention deficit/hyperactivity disorder (ADHD).

146 sk factors (major depressive disorder [MDD], attention deficit/hyperactivity disorder [ADHD], bipolar

147 d 3.3-fold (95% CI: 1.4, 7.7) higher odds of attention deficit/hyperactivity disorder problems compar

148 elligence quotient (IQ) and higher levels of attention deficit/hyperactivity disorder symptoms.

149 y, as it was associated with lower levels of attention deficit/hyperactivity disorder symptoms.

150 opmental disorders, including schizophrenia, attention deficit/hyperactivity disorder, and autism spe

151 neurologic disorders in offspring, including attention deficit/hyperactivity disorder, autism, and sc

152 tives, central nervous system stimulants for attention deficit/hyperactivity disorder, disease-modify

153 nxiety disorders, autism spectrum disorders, attention deficit/hyperactivity disorder, severe learnin

154 renia, bipolar disorder, autism, anxiety and attention deficit/hyperactivity disorder.

155 ehavioural addictions, eating disorders, and attention deficit/hyperactivity disorder.

156 [0.2%]; adjusted RR, 4.3; 95% CI, 2.3-8.2), attention-deficit/hyperactivity disorder (189 cases [5.3

157 ar bipolar disorder (94.2 [1.69]; P = .004), attention-deficit/hyperactivity disorder (96.3 [0.91]; P

158 ofiles in autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) - preval

159 Attention-deficit/hyperactivity disorder (ADHD) affects

160 Attention-deficit/hyperactivity disorder (ADHD) and anxi

161 Attention-deficit/hyperactivity disorder (ADHD) and auti

162 ified the first genetic loci associated with attention-deficit/hyperactivity disorder (ADHD) and auti

163 fferential diagnosis between childhood onset attention-deficit/hyperactivity disorder (ADHD) and bipo

164 Attention-deficit/hyperactivity disorder (ADHD) and bipo

165 Attention-Deficit/Hyperactivity Disorder (ADHD) and cond

166 Although attention-deficit/hyperactivity disorder (ADHD) and eati

167 dication has long been effective in treating attention-deficit/hyperactivity disorder (ADHD) and is c

168 ight the role of excessive mind wandering in attention-deficit/hyperactivity disorder (ADHD) and its

169 Patients with attention-deficit/hyperactivity disorder (ADHD) and obse

170 lphenidate (MPH) is used clinically to treat attention-deficit/hyperactivity disorder (ADHD) and off-

171 It frequently co-occurs with attention-deficit/hyperactivity disorder (ADHD) and ofte

172 Autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD) are asso

173 Patients with attention-deficit/hyperactivity disorder (ADHD) are at a

174 Individuals with attention-deficit/hyperactivity disorder (ADHD) are at g

175 SD), obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) are clin

176 earch has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more

177 Epilepsy and attention-deficit/hyperactivity disorder (ADHD) are stro

178 atric symptoms of anxiety, irritability, and attention-deficit/hyperactivity disorder (ADHD) as commo

179 been implicated in the etiology of clinical attention-deficit/hyperactivity disorder (ADHD) diagnose

180 Attention-deficit/hyperactivity disorder (ADHD) diagnosi

181 Attention-deficit/hyperactivity disorder (ADHD) frequent

182 Autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD) frequent

183 Attention-deficit/hyperactivity disorder (ADHD) has an u

184 Although the prevalence of attention-deficit/hyperactivity disorder (ADHD) has been

185 Neuroimaging studies of attention-deficit/hyperactivity disorder (ADHD) have mos

186 ic resonance imaging (fMRI) studies of adult attention-deficit/hyperactivity disorder (ADHD) have rev

187 volumetric differences were associated with attention-deficit/hyperactivity disorder (ADHD) in a rec

188 cetaminophen in pregnancy has been linked to attention-deficit/hyperactivity disorder (ADHD) in child

189 lar pertussis (Tdap) vaccination and risk of attention-deficit/hyperactivity disorder (ADHD) in offsp

190 Stimulant medications used to treat attention-deficit/hyperactivity disorder (ADHD) increase

191 Attention-deficit/hyperactivity disorder (ADHD) is a com

192 Attention-Deficit/Hyperactivity Disorder (ADHD) is a com

193 Importance: Attention-deficit/hyperactivity disorder (ADHD) is a her

194 Attention-deficit/hyperactivity disorder (ADHD) is a maj

195 Attention-deficit/hyperactivity disorder (ADHD) is a neu

196 Attention-deficit/hyperactivity disorder (ADHD) is a pre

197 Attention-deficit/hyperactivity disorder (ADHD) is a ris

198 Attention-deficit/hyperactivity disorder (ADHD) is a sev

199 Attention-deficit/hyperactivity disorder (ADHD) is an im

200 Attention-deficit/hyperactivity disorder (ADHD) is assoc

201 Attention-deficit/hyperactivity disorder (ADHD) is assoc

202 Recognition that adult attention-deficit/hyperactivity disorder (ADHD) is commo

203 Attention-deficit/hyperactivity disorder (ADHD) is emble

204 show that age-related change in symptoms of attention-deficit/hyperactivity disorder (ADHD) is herit

205 p between autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) is incre

206 Attention-deficit/hyperactivity disorder (ADHD) is now r

207 Attention-deficit/hyperactivity disorder (ADHD) is the m

208 Attention-deficit/hyperactivity disorder (ADHD) medicati

209 Attention-deficit/hyperactivity disorder (ADHD) often pe

210 Symptoms of attention-deficit/hyperactivity disorder (ADHD) run a va

211 Attention-deficit/hyperactivity disorder (ADHD) shows su

212 ated the link between putative biomarkers of attention-deficit/hyperactivity disorder (ADHD) symptoma

213 Attention-deficit/hyperactivity disorder (ADHD) symptoms

214 based on network strength at rest predicted attention-deficit/hyperactivity disorder (ADHD) symptoms

215 ted polygenic risk scores (PRSs) for ASD and attention-deficit/hyperactivity disorder (ADHD) using ge

216 th body fat % and fat-free mass, whereas (2) attention-deficit/hyperactivity disorder (ADHD), alcohol

217 Additional, inconstant features include attention-deficit/hyperactivity disorder (ADHD), autism,

218 to investigate the genetic susceptibility of Attention-Deficit/Hyperactivity Disorder (ADHD), but wit

219 phenidate hydrochloride for the treatment of attention-deficit/hyperactivity disorder (ADHD), little

220 eorized to be greater among individuals with attention-deficit/hyperactivity disorder (ADHD), potenti

221 ivity, a multifaceted behavioral hallmark of attention-deficit/hyperactivity disorder (ADHD), strongl

222 er to better understand the underpinnings of attention-deficit/hyperactivity disorder (ADHD), we targ

223 atric disorders, particularly drug abuse and attention-deficit/hyperactivity disorder (ADHD).

224 eportedly associated with the development of attention-deficit/hyperactivity disorder (ADHD).

225 ultiple neuropsychiatric disorders including attention-deficit/hyperactivity disorder (ADHD).

226 nidate (MPH) is highly effective in treating attention-deficit/hyperactivity disorder (ADHD).

227 ion, the dysfunction of which is a factor in attention-deficit/hyperactivity disorder (ADHD).

228 sociation between atopic dermatitis (AD) and attention-deficit/hyperactivity disorder (ADHD).

229 ity, few risk genes have been identified for attention-deficit/hyperactivity disorder (ADHD).

230 lfated form (DHEA-S), and characteristics of attention-deficit/hyperactivity disorder (ADHD).

231 ms observed in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

232 chiatric disorders and could be relevant for attention-deficit/hyperactivity disorder (ADHD).

233 Genetic factors predispose individuals to attention-deficit/hyperactivity disorder (ADHD).

234 eart rate variability (HRV) in children with Attention-Deficit/Hyperactivity Disorder (ADHD).

235 dentified structural changes associated with attention-deficit/hyperactivity disorder (ADHD).

236 The hD4.7 variant has been linked to attention-deficit/hyperactivity disorder (ADHD); however

237 disorder (HR, 0.83 [95% CI, 0.62-1.13]), or attention-deficit/hyperactivity disorder (HR, 0.99 [95%

238 or diagnosed with bipolar disorder (n = 40), attention-deficit/hyperactivity disorder (n = 37), schiz

239 h schizophrenia (N=3540), autism (N=16 146), attention-deficit/hyperactivity disorder (N=18 726) and

240 r (R(2) = .11%, p empirical = .11, Q = .15), attention-deficit/hyperactivity disorder (R(2) = .09%, p

241 Attention-deficit/hyperactivity disorder according to DS

242 disorders, including infantile parkinsonism, attention-deficit/hyperactivity disorder and autism spec

243 of all other disorders were observed in both attention-deficit/hyperactivity disorder and autism spec

244 Some conditions, such as attention-deficit/hyperactivity disorder and inpatient w

245 impulsivity, and inattention associated with attention-deficit/hyperactivity disorder and may likewis

246 Attention-deficit/hyperactivity disorder and well-dental

247 ants for schizophrenia, bipolar disorder and attention-deficit/hyperactivity disorder are located in

248 ed vs 5.46% of unexposed were diagnosed with attention-deficit/hyperactivity disorder by age 15 years

249 e drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and anti

250 for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepr

251 The adult form of attention-deficit/hyperactivity disorder has a prevalenc

252 hazard ratio [HR], 2.02 [95% CI, 1.80-2.26]; attention-deficit/hyperactivity disorder HR, 2.21 [95% C

253 ence of gestational age in later symptoms of attention-deficit/hyperactivity disorder in 105 individu

254 ession and anxiety, aggressive behavior, and attention-deficit/hyperactivity disorder in children wer

255 disorders such as schizophrenia, autism, and attention-deficit/hyperactivity disorder in humans.

256 al diagnosis of autism spectrum disorder and attention-deficit/hyperactivity disorder in offspring.

257 t gestational age predicts later symptoms of attention-deficit/hyperactivity disorder in the euploid

258 Attention-deficit/hyperactivity disorder is frequently r

259 Attention-deficit/hyperactivity disorder severity was re

260 tion (outlier magnitude) relates to specific attention-deficit/hyperactivity disorder symptoms (hyper

261 s studies have reported associations between attention-deficit/hyperactivity disorder symptoms and DN

262 symptoms, aggressive behavior symptoms, and attention-deficit/hyperactivity disorder symptoms within

263 ession and anxiety, aggressive behavior, and attention-deficit/hyperactivity disorder symptoms, a one

264 ide association study meta-analysis of adult attention-deficit/hyperactivity disorder symptoms, based

265 h highest precision when cases with comorbid attention-deficit/hyperactivity disorder were removed fr

266 sorder, bipolar disorder, schizophrenia, and attention-deficit/hyperactivity disorder).

267 , major depressive disorder, cross disorder, attention-deficit/hyperactivity disorder, and anorexia n

268 pes of care and inpatient well-newborn care, attention-deficit/hyperactivity disorder, and asthma amo

269 m severity of obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, and autism spe

270 rodevelopmental disorders, including autism, attention-deficit/hyperactivity disorder, and schizophre

271 ld be addressed when considering symptoms of attention-deficit/hyperactivity disorder, as it may have

272 ts with a psychiatric diagnosis of interest (attention-deficit/hyperactivity disorder, autism spectru

273 major depressive disorder, bipolar disorder, attention-deficit/hyperactivity disorder, autism spectru

274 orders, such as autism spectrum disorder and attention-deficit/hyperactivity disorder, but is much le

275 between them and schizophrenia, depression, attention-deficit/hyperactivity disorder, eating disorde

276 Associations of clinical symptom scales (attention-deficit/hyperactivity disorder, psychosis, dep

277 the genetic signature of DD overlapped with attention-deficit/hyperactivity disorder, schizophrenia,

278 s, such as Parkinson's disease, obesity, and attention-deficit/hyperactivity disorder, were character

279 ss exacerbates symptoms of schizophrenia and attention-deficit/hyperactivity disorder, which are char

280 e of the associations, with the exception of attention-deficit/hyperactivity disorder, which attenuat

281 disorder, depression, anxiety disorders, and attention-deficit/hyperactivity disorder.

282 disorders including depression, anxiety, and attention-deficit/hyperactivity disorder.

283 sorder, and attention and cognition, such as attention-deficit/hyperactivity disorder.

284 ic tracts in brain white matter in boys with attention-deficit/hyperactivity disorder.

285 on models or after the exclusion of comorbid attention-deficit/hyperactivity disorder.

286 cluding schizophrenia, bipolar disorder, and attention-deficit/hyperactivity disorder.

287 estational age, autism spectrum disorder, or attention-deficit/hyperactivity disorder.

288 analysis, of whom 25 (4.8%) met criteria for attention-deficit/hyperactivity disorder.

289 olar disorder, major depressive disorder, or attention-deficit/hyperactivity disorder.

290 ntinuous Performance Test and diagnosis with attention-deficit/hyperactivity disorder.

291 ines, particularly in patients with comorbid attention-deficit/hyperactivity disorder.

292 d increase the risk of anxiety disorders and attention-deficit/hyperactivity disorder.

293 xiety, disruptive mood dysregulation, and/or attention-deficit/hyperactivity disorders and 22 healthy

294 elate to anxiety, depression, psychosis, and attention-deficit/hyperactivity symptoms.

295 d Interview for Prodromal Syndromes, and for attention-deficit/hyperactivity, substance-related, and

296 the neurological expression of neglect-like attention deficits in macaques, we measured attention-re

297 e effect of oxytocin on reversing non-social attention deficits is a particularly novel finding, and

298 n contrast, we observed no associations with attention deficits or depressive, manic, or obsessive-co

299 Attention deficit recovery was mostly complete by 3 mont

300 Attention deficits were significantly more correlated wi